UNSPSC 51183202: Alogliptin benzoate

This classification denotes an anti-diabetic agent C18H21N5O2.C7H6O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EEN99869SC, chemically known as benzonitrile, 2-((6-((3r)-3-amino-1-piperidinyl)-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl)methyl)-, monobenzoate, but more generally known as alogliptin benzoate, which bears US NIH Compound Identifier 16088021. European Medicines Agency schedules Alogliptin benzoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32165.

UNSPSC 51183202 Alogliptin benzoate is a Commodity code that captures pharmaceuticals supplied through cooperative purchasing agreements to state and local government healthcare facilities. State and local procurement under this code focuses on generic multi-source pharmaceuticals and over-the-counter products distributed across participating agencies, including state departments of administration and health systems. The work involves sourcing from manufacturers who meet cGMP and Drug Supply Chain Security Act compliance requirements and maintain relationships with authorized pharmaceutical wholesalers to support government healthcare operations. Issuing bodies include state purchasing offices administering multistate cooperative purchasing alliances and the participating member jurisdictions that draw on those agreements.

Recent activity centers on the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, which issued an RFP on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products effective July 1, 2026. The MMCAP RFP requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and extends to participating states including Oregon. The proposal evaluation weights price competitiveness at 75 percent, with the remaining 25 percent split among fixed pricing, administrative compliance, EDI capability, and administrative fee acceptance. Vendors must maintain commercial general liability coverage of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, with products required to possess expiration dates of at least one year from manufacture. Proposals were due March 26, 2026, with a question cutoff of February 18, 2026.